HomeCompareBMY vs HES

BMY vs HES: Dividend Comparison 2026

BMY yields 4.17% · HES yields 1.34%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HES wins by $755.7K in total portfolio value· pulled ahead in Year 6
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
HES
HES
● Live price
1.34%
Share price
$148.97
Annual div
$2.00
5Y div CAGR
79.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$876.2K
Annual income
$619,272.65
Full HES calculator →

Portfolio growth — BMY vs HES

📍 HES pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYHES
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + HES cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
HES pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
HES
Annual income on $10K today (after 15% tax)
$114.12/yr
After 10yr DRIP, annual income (after tax)
$526,381.75/yr
At 15% tax rate, HES beats the other by $492,531.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + HES for your $10,000?

BMY: 50%HES: 50%
100% HES50/50100% BMY
Portfolio after 10yr
$498.4K
Annual income
$329,548.15/yr
Blended yield
66.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HES right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
HES
Analyst Ratings
18
Buy
30
Hold
Consensus: Hold
Price Target
$148.19
-0.5% upside vs current
Range: $86.00 — $199.00
Altman Z
3.1
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
HES buys
0
No recent congressional trades found for BMY or HES in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYHES
Forward yield4.17%1.34%
Annual dividend / share$2.49$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%79.8%
Portfolio after 10y$120.5K$876.2K
Annual income after 10y$39,823.66$619,272.65
Total dividends collected$91.0K$831.8K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold
Analyst price target$62.73$148.19

Year-by-year: BMY vs HES ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrHES PortfolioHES Income/yrGap
1$11,271$571.12$10,941$241.39+$330.00BMY
2$12,884$824.20$12,151$443.81+$733.00BMY
3$14,993$1,206.32$13,830$828.22+$1.2KBMY
4$17,839$1,797.27$16,382$1,584.01+$1.5KBMY
5$21,826$2,738.11$20,682$3,152.91+$1.1KBMY
6← crossover$27,643$4,289.31$28,818$6,688.61$1.2KHES
7$36,534$6,955.64$46,496$15,661.01$10.0KHES
8$50,861$11,770.13$92,211$42,460.02$41.4KHES
9$75,402$20,980.23$240,164$141,498.19$164.8KHES
10$120,504$39,823.66$876,248$619,272.65$755.7KHES

BMY vs HES: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

HESStock

Hess Corporation, an exploration and production company, explores, develops, produces, purchases, transports, and sells crude oil, natural gas liquids (NGLs), and natural gas. The company operates in two segments, Exploration and Production, and Midstream. It conducts production operations primarily in the United States, Guyana, the Malaysia/Thailand Joint Development Area, and Malaysia; and exploration activities principally offshore Guyana, the U.S. Gulf of Mexico, and offshore Suriname and Canada. The company is also involved in gathering, compressing, and processing natural gas; fractionating NGLs; gathering, terminaling, loading, and transporting crude oil and NGL through rail car; and storing and terminaling propane, as well as providing water handling services primarily in the Bakken Shale plays in the Williston Basin area of North Dakota. As of December 31, 2021, it had total proved reserves of 1,309 million barrels of oil equivalent. The company was incorporated in 1920 and is headquartered in New York, New York.

Full HES Calculator →
📬

Get this BMY vs HES comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.